American Society of Hematology

Figure 1.

$Figure 1. ADP receptors and GPIIb/IIIa participate in collagen-induced TF presentation in whole blood. (A) Whole blood was activated for 10 minutes at 37°C with collagen (coll; 10 μg/mL). To the samples with collagen alone, vehicle was added corresponding to the amount of buffer required to suspend the ADP receptor antagonists. In further samples, collagen plus either MRS-2179 (1 mM) or AR-C69931MX (10 μM) was added. Thereafter, the number of TF-positive leukocytes was determined among the total fraction of CD45+ cells. Co indicates control. Means ± SDs; n = 5to8.*P < .05 (versus collagen alone). (B) Effect of abciximab (ab) (20 μg/mL), MRS-2179 (1 mM), and AR-C69931MX (10 μM) on leukocyte TF exposure. Whole blood was stimulated for 10 minutes at 37°C with collagen (10 μg/mL). Means ± SDs; n = 3. *P < .05 (versus collagen alone); §P < .05 (versus abciximab).$

ADP receptors and GPIIb/IIIa participate in collagen-induced TF presentation in whole blood. (A) Whole blood was activated for 10 minutes at 37°C with collagen (coll; 10 μg/mL). To the samples with collagen alone, vehicle was added corresponding to the amount of buffer required to suspend the ADP receptor antagonists. In further samples, collagen plus either MRS-2179 (1 mM) or AR-C69931MX (10 μM) was added. Thereafter, the number of TF-positive leukocytes was determined among the total fraction of CD45⁺ cells. Co indicates control. Means ± SDs; n = 5to8.*P < .05 (versus collagen alone). (B) Effect of abciximab (ab) (20 μg/mL), MRS-2179 (1 mM), and AR-C69931MX (10 μM) on leukocyte TF exposure. Whole blood was stimulated for 10 minutes at 37°C with collagen (10 μg/mL). Means ± SDs; n = 3. *P < .05 (versus collagen alone); §P < .05 (versus abciximab).

This Feature Is Available To Subscribers Only